[Preeclampsia: Should screening and pronostic biomarkers be used in common clinical practice?]

Presse Med. 2019 Oct;48(10):1032-1036. doi: 10.1016/j.lpm.2019.09.029. Epub 2019 Oct 30.
[Article in French]
No abstract available

Publication types

  • Review

MeSH terms

  • Angiogenic Proteins / antagonists & inhibitors
  • Angiogenic Proteins / metabolism
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Aspirin / therapeutic use
  • Biomarkers / blood*
  • Biomarkers / metabolism
  • Female
  • Humans
  • Pre-Eclampsia / blood*
  • Pre-Eclampsia / diagnosis*
  • Pre-Eclampsia / etiology
  • Pre-Eclampsia / physiopathology
  • Pregnancy
  • Pregnancy Trimester, First
  • Pregnancy Trimester, Second
  • Pregnancy Trimester, Third
  • Prevalence
  • Prognosis
  • Vascular Endothelial Growth Factor A / blood
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Angiogenic Proteins
  • Anti-Inflammatory Agents, Non-Steroidal
  • Biomarkers
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Aspirin